This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrowReprints and Permissions
Right arrow Copyright Information
Right arrow Books from ASM Press
Right arrow MicrobeWorld
Google Scholar
Right arrow Articles by Xu, P.
Right arrow Articles by Gao, Q.
PubMed
Right arrow PubMed Citation
Right arrow Articles by Xu, P.
Right arrow Articles by Gao, Q.

 Previous Article  |  Next Article 

Antimicrobial Agents and Chemotherapy, July 2009, p. 3170-3172, Vol. 53, No. 7
0066-4804/09/$08.00+0     doi:10.1128/AAC.00177-09
Copyright © 2009, American Society for Microbiology. All Rights Reserved.

Prevalence of Fluoroquinolone Resistance among Tuberculosis Patients in Shanghai, China {triangledown}

Peng Xu,1,2,{dagger} Xia Li,2,{dagger} Ming Zhao,1,2 Xiaohong Gui,1 Kathryn DeRiemer,3 Sebastien Gagneux,4 Jian Mei,1* and Qian Gao2*

Department of TB Control, Shanghai Municipal Center for Disease Control and Prevention, Shanghai 200336, China,1 Key Laboratory of Medical Molecular Virology, Institutes of Biomedical Sciences and Institute of Medical Microbiology, Fudan University, Shanghai 200032, People's Republic of China,2 School of Medicine, University of California, One Shields Avenue, Davis, California 95616,3 Division of Mycobacterial Research, MRC National Institute for Medical Research, Mill Hill, London NW7 1AA, United Kingdom4

Received 9 February 2009/ Returned for modification 9 March 2009/ Accepted 6 April 2009

We determined the prevalence of fluoroquinolone resistance among the isolates of Mycobacterium tuberculosis from 605 pulmonary tuberculosis patients in Shanghai, China. Mutations in gyrA were found in 81.5% of phenotypically fluoroquinolone-resistant isolates and were used as a molecular marker of fluoroquinolone resistance. gyrA mutations were detected in 1.9% of strains pan-susceptible to first-line drugs and 25.1% of multidrug-resistant strains. Fluoroquinolone resistance was independently associated with resistance to at least one first-line drug and prior tuberculosis treatment.

* Corresponding author. Mailing address for Qian Gao: Key Laboratory of Medical Molecular Virology, Shanghai Medical College, Fudan University, Shanghai 200032, China. Phone: (8621) 5423-7195. Fax: (8621) 5423-7971. E-mail: qgao99{at}yahoo.com. Mailing address for Jian Mei: Department of TB Control, Shanghai Municipal Center for Disease Control and Prevention, Shanghai 200336, China. Phone: (8621) 6275-8710. Fax: (8621) 6278-1851. E-mail: meijiansh{at}yahoo.com.cn

{triangledown} Published ahead of print on 13 April 2009.

{dagger} These two persons contributed equally to this article.

Antimicrobial Agents and Chemotherapy, July 2009, p. 3170-3172, Vol. 53, No. 7
0066-4804/09/$08.00+0     doi:10.1128/AAC.00177-09
Copyright © 2009, American Society for Microbiology. All Rights Reserved.





Copyright © 2009 by the American Society for Microbiology.   For an alternate route to Journals.ASM.org, visit: http://intl-journals.asm.org | More Info»